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ABSTRACT
Non-communicable diseases (NCDs) (also known as socially transmitted diseases) were con-
spicuously absent from the Millennium Development Goals and seemed to miss out on the
‘golden years’ of health funding despite causing more death and disability than any other
disease group worldwide. The share of ‘development assistance for health’ dedicated to NCDs
has remained at 1–2% of the total since 2000. This level of funding is insufficient to attain the
nine targets in the World Health Organization (WHO) Global Action Plan on NCDs. In 2015 the
Sustainable Development Goals – which include the target of reducing premature NCD
mortality by a third – were endorsed by 193 countries. Whilst this commitment is welcome,
the same text stresses the primacy of domestic financing, which is currently dominated by
out-of-pocket payments in low- and middle-income countries (LMICs). This paper presents the
findings of the WHO Global Coordination Mechanism on NCDs financing working group. The
group was convened to explore NCD financing options with an emphasis on LMICs. The main
sources of available finance include taxation, loans, engagement with the private sector,
impact investment and innovative financing mechanisms. There is a role for development
assistance to increase in the interim as raising additional revenue from these sources will take
time. In the medium term it may be appropriate for international NCD funding to remain low
where LMICs successfully assume financial responsibility for preventing and controlling NCDs.
Countries will have to manage blends of innovative and traditional funding sources, whilst
finding ways to boost tax revenue for NCDs.
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Non-communicable diseases (NCDs) have come to
dominate the global burden of disease but the pro-
portion of all global health financing dedicated to
combatting the pandemic has remained constant
over the past 15 years at 1–2% [1]. In 2011 ministers
responded to this persistent gap at the United
Nations (UN) High-Level Meeting on NCDs by com-
mitting to ‘explore the provision of adequate, predict-
able and sustained resources, through domestic,
bilateral, regional and multilateral channels, includ-
ing traditional and voluntary innovative financing
mechanisms’ [2]. As the Sustainable Development
Agenda stresses domestic responsibility for financing,
a surge in overseas NCD spending looks increasingly
unlikely [3]. This article presents findings from the
expert Working Group convened under the auspices
of the World Health Organization (WHO) Global
Coordination Mechanism (GCM) on NCDs to exam-
ine the current NCD financing landscape and explore
sources of funding available to support domestic
NCD responses in the Sustainable Development era.
The mandate for the report stems from paragraph 45
(d) of the Political Declaration of the High-level
Meeting of the UN General Assembly on the
Prevention and Control of NCDs: ‘to explore the
provision of adequate, predictable and sustained
resources, through domestic, bilateral, regional and
multilateral channels, including traditional and
voluntary innovative financing mechanisms’.
The Working Group was chaired by the US health
attaché to the UN and the director of health policy
research at India’s Institute of Economic Growth. The
12 globally representative members were selected by
their home countries and approved by the WHO
Director General. The final report was written by
Professor Rachel Nugent. This article summarises
the findings and situates them in the contemporary
financing landscape.
Non-communicable diseases (NCDs)
Four main conditions account for over 80% of NCD
deaths: cancers, respiratory diseases, type II diabetes
and cardiovascular disease. These conditions share
four common behavioural risk factors: physical inac-
tivity, poor diet, tobacco and excessive alcohol use
[4]. In September 2011 ministers acknowledged that
NCDs are one of the most pressing development
challenges facing mankind [2].
These conditions cause around two thirds of all
global deaths and 16 million of these are premature
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[5]. At the confluence of epidemiological, demo-
graphic and economic transitions, low- and middle-
income countries (LMICs) experience higher absolute
and relative rates of premature death and disability
from NCDs [6,7].
The NCD pandemic also levies a heavy toll on
international finances. From 2011 to 2025 it is esti-
mated that NCDs will drain over US$ 50 trillion from
the global economy [8]. Fortunately, preventing
NCDs is very cheap in comparison with the costs of
inaction. The WHO’s population-level NCD ‘best
buy’ interventions cost US$ < 0.20 per capita per
year in low-income countries and US$ < 0.50 in
middle-income countries [9]. Scaling up the best
buys from 5% to 80% coverage in all LMICs would
cost US$ 11.4 billion – less than 5% of current annual
health expenditure and almost on par with the
leviathan cost of inaction [10,11].
The contemporary NCD financing landscape
In 2014 NCDs constituted half of the entire global
burden of disease, but received less than 2% of all
international health aid (US$ 492 million out of US$
36 billion) [1]. In contrast, HIV represented 4% of the
global burden of disease but received 29% of global
funds (Figure 1) [5].
Of the $475 million overseas funding devoted to
NCDs in 2015, $128 million was provided for mental
health and $41million for tobacco-control [1]. Almost a
fifth of NCD funding is from private philanthropy:
other major donors include the Gates Foundation and
the US and UK governments. These data come from the
foremost global health financing accountant; the
Seattle-based Institute for Health Metrics and
Evaluation (IHME) [12]. The IHME database does not
count money that goes towards NCDs that falls under
other headings such as ‘health sector support’ and
‘other’, leading to an underestimation of NCD funding.
Independent research suggests that overseas NCD
financing may be up to 2.5 times higher than currently
estimated (although this would still be a mere 3.25% of
global health financing) [13,14]. Ministers at the UN
General Assembly have asked the Organisation for
Economic Co-operation and Development (OECD)
Development Assistance Committee to formally track
overseas funding to overcome these accounting
issues [15].
Data on domestic NCD financing are even scarcer
than overseas assistance data. This is despite the fact
that domestic financing constitutes 75% of overall
health spending in low-income countries and 97%
in lower-middle-income countries (where the global
burden of NCDs is greatest) [16,17].
In many countries the largest component of domes-
tic health funding comes from over-the-counter pay-
ments as patients pay for their own care as and when
costs arise. These so called ‘out-of-pocket’ payments
contrast with medical insurance (‘pre-pooling’) and
can be financially crippling in the case of chronic dis-
eases that require ongoing treatment with expensive
medication. Out-of-pocket payments account for 48%
of all health expenditure in low-income countries, 36%
in middle-income countries and 15% in high-income
countries [18]. Despite the fact that NCDs have been the
leading cause ofmortality inmost countries for decades,
only half ofWHOmember states hadNCD line items in
their health budgets in 2011 [19].
Nugent and Brouwer caution that the NCD-related
target (Target 3.4) in the UN Sustainable
Development Goals (SDGs) cannot be achieved if
funding for NCDs does not increase [20]. Their eco-
nomic analysis found NCD preventive interventions
are expensive to implement but highly cost-effective.
Funding the post-2015 NCD response
The high-level UN commitment to find new and
sustainable sources of NCD financing led to the
establishment of the aforementioned expert NCD
funding working group, convened under the auspices
of the WHO GCM on NCDs. The group identified









Figure 1. The share of disability adjusted life years (DALYs) and overseas development assistance for health (DAH) for five major
disease groups.
Data source: Institute for Health Metrics and Evaluation DAH database.
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Domestic
The working group’s report strongly argues that pre-
payment (i.e. insurance) and government provision
should replace out-of-pocket expenditure (paying
upfront when ill) as the dominant source of NCD
funding within LMICs [21]. The chronic nature of
NCDs and the high costs of diagnosis and treatment
impose heavy financial burdens on impoverished house-
holds. Socioeconomic inequalities are exacerbated,
families are pushed further into poverty and many
simply go without care in settings where out-of-pocket
payment is the major source of financing [22–24].
The working group noted that government expen-
diture is 20.5% of GDP in advanced economies and
16.5% in low-income countries [25]. For govern-
ments to assume a greater role in providing NCD
prevention and control services – in line with com-
mitments made in 2011, 2014 and 2015 [26–28] –
they must raise more revenue for NCDs. The GCM
working group identified three ways to meet this aim.
Firstly, governments should seek to allocate a
greater share of public funds to NCD control efforts.
Signatories of the Abuja Declaration have committed
to spending 15% of their annual budget on health and
more countries could follow suit in this area [29]. As
government revenue grows, additional revenue
should preferentially flow to NCDs where these are
the leading causes of morbidity and mortality.
Secondly, governments should try to capture the
‘economic dividend’ as continued economic growth
generates new funds that can be channelled to fight-
ing NCDs. Over the next two decades the gross
domestic product (GDP) of low-income countries is
predicted to increase by US$ 1 trillion.
Approximately US$ 9 trillion is expected in lower-
middle-income countries over the same time period
[30]. If tax agencies can collect a share of this divi-
dend, additional resources can be used to increase
public spending in all areas.
Thirdly, there is scope for a number of LMICs to
raise additional revenue for government spending.
There are many ways to boost fiscal capacity includ-
ing improving tax compliance and the efficiency of
revenue collection, increasing tax rates and broaden-
ing the tax base, introducing social health insurance
contributions for health services, and introducing
excise taxes on tobacco, alcohol and unhealthy foods
and beverages.
Increased revenue from taxation and long-term
economic growth, coupled with commitments to pro-
portionally increase the amount of government
expenditure earmarked for NCDs, represents the
most sustainable way of financing NCD prevention
and control in LMICs.
The working group also encouraged governments
to monitor NCD expenditure across all state
departments (akin to tracking all sources of overseas
funding) and to prioritise poverty reduction strategies
that target NCDs. They also encouraged governments
to set NCD investment targets and to record this
spending in National Health Accounts.
Whilst governments have committed to take the
lead in financing national NCD responses, there are
many sources of external financing that can make up
the shortfall in the short to medium term. These
measures are covered in the following sections.
Overseas development assistance
Donor assistance is an important source of funding,
but it can also help to build capacity in LMICs.
Shared experts, experience, equipment and
approaches can bolster national NCD responses in
countries with limited domestic resources [31].
Emerging donors, including BRICS countries
(Brazil, Russia, India, China, South Africa) and the
Gulf States, are becoming more important in terms of
both South–South financial support and in sharing
their experience of low-cost approaches to managing
NCDs [14,16]. The GCM working group also
endorsed the target of spending 0.7% of gross
national income on aid. Recipient countries can
help by creating clear health performance metrics to
offer donors, combined with economic performance
measures.
Development loans
Development banks are already transitioning from
Millennium Development Goals (where NCDs were
conspicuously absent) towards the SDGs that include
reducing premature NCD mortality by a third [32].
Even in the last year over 20 NCD-inclusive loans
worth hundreds of millions of dollars have been
supplied by lenders such as the World Bank and the
Inter-American Development Bank [33]. Countries
have a renewed mandate to apply for international
development financing in SDG Target 3.4 and a
strong investment case as NCD interventions typi-
cally deliver high returns [21].
Engaging the private sector
Private capital can be mobilised for NCDs in many
ways. Many commercial entities have objectives that
closely align with the NCD agenda, such as those
operating in the fitness sector, those selling fruits
and vegetables, and certain actors in the pharmaceu-
tical industry. Engagement with these businesses can
promote the NCD prevention agenda at no cost to
the public purse.
Public–private partnerships can raise additional
funds for fighting NCDs in countries that are ineligible
for traditional donor support. Using public–private
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partnerships to deliver NCD-related public goods can
also increase service quality and release previously
untapped sources of private capital [34].
Innovative financing mechanisms
A broad array of novel financing Initiatives have
emerged in recent decades including micro-levies on
airplane tickets, credit card rounding plans, and large
financing mechanisms like the Global Fund to Fight
AIDS, Tuberculosis and Malaria. The UN has made a
concerted effort to foster development financing
mechanisms that ‘are stable, long-term, that comple-
ment official public aid, and that widen the shared
benefits of globalisation’ [35,36]. Over US$ 7 billion
has been generated for global health issues over the
last 15 years using non-traditional financing mechan-
isms [37]. The innovative financing mechanisms cap-
able of generating additional funds for NCDs broadly
fall into the following three categories.
Voluntary contributions
Options include credit card plans that round bills up
to the nearest dollar and donate the excess monies;
lotteries where all profit goes to a specific cause; and
the use of targeted marketing schemes to raise addi-
tional funds. These innovative ways of raising chari-
table donations from the general public and
corporate sponsors usually earmark funds for a spe-
cific use. NCD examples include ‘Go Red for Women’
targeting heart disease and the ‘Pink Ribbon’ cam-
paign for breast cancer.
Compulsory levies or taxes
An increasing number of countries are applying ‘sin
taxes’ to unhealthy products and using the revenue to
promote health. Hypothecated excise taxes on
tobacco, alcohol and sugary drinks can all raise
money for NCDs whilst promoting prevention [38].
At the international level there is appetite for further
hypothecated levies following the UNITAID model of
collecting revenue from airline tickets [39]. A mooted
Solidarity Tobacco Contribution ‘micro levy’ aims to
skim a small percentage from tobacco purchases to
raise money for health initiatives [40].
Financial mechanisms and facilities
This broad category includes funds from sustainable
and impact investing sectors. Microfinance initiatives
are an example of a financial mechanism that releases
funds to achieve development aims on the local level
with private capital from (traditionally) Northern
investors. Large financing facilities such as the
GAVI Alliance and the Global Fund to Fight AIDS,
Tuberculosis and Malaria use a mix of public–private
financing and international loans to raise capital.
There is a paucity of innovative financing mechan-
isms currently focused on NCDs; however, the Global
Alliance for Clean Cookstoves Spark Fund is one
example [41]. Impact investment in the health sector
can benefit NCD responses indirectly by bolstering
health systems, primary care and human resources
[42]. The market for impact investment in health is
large (estimated at US$ 18–123 billion) and is set to
expand significantly over coming years [43].
All of the above initiatives can be implemented glob-
ally or nationally; however, at every stage there is a risk
that contributions will represent reallocations rather than
net additions to NCD financing. The working group calls
for new additional overseas funds for NCDs rather than
reallocation e.g. by redirecting funds fromHIV toNCDs.
This issue also exists at the national level, especially as
most of theworking group’s recommendations pertain to
raising general government revenue rather than specific
NCD funds. Health and finance ministers will have to
exercise discipline in ringfencing new funds for NCDs,
rather than spending in other sectors.
Directly switching resources from, say, HIV towards
NCDswould disrupt established programmes and lead to
conflict between health allies. As the global health com-
munity shifts emphasis from ‘vertical’ disease-specific
funding towardsmore ‘horizontal’health system support,
NCDs are likely to indirectly benefit. This is because
strong health systems are required for prevention, screen-
ing, detection, treatment, rehabilitation and palliation.
Many of these activities are underdeveloped in LMICs.
The establishment of new cadres of health workers, facil-
ities and equipmentwill benefit patients suffering fromall
conditions; however, as these services already exist for
those with TB but are largely absent for NCDs like
hypertension, NCD patients will disproportionately ben-
efit. The same is true for nascentmoves to bolster primary
care, and from the universal health coverage movement.
A further issue in NCD financing is the sustainabil-
ity of any new funds. Overseas allocations are based on
a set of ever-changing priorities or the whim of private
philanthropists. International financing schemes are
dependent on market confidence and the performance
of the global economy. Government budgets tend to
change with every election, and the demographic tran-
sition – well underway in countries like China and
Bangladesh – will see old-age dependency ratios rise
sharply in the coming decades.
Conclusion
To meet their political commitments to reduce the
burden of NCDs, LMICs will have to utilise multiple
financing sources. The exact blend of the sources
described here will depend on political objectives, fiscal
capacity, the domestic burden of disease and the nature
of existing relationships with international donors.
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The Addis Ababa agreement laid the groundwork for
an international agenda that increasingly stresses domes-
tic responsibility for financing. The inward-looking
Trump administration in the US has provided additional
impetus to strengthen domestic revenue collection. In
light of these developments, the first question for many
countries is whether domestic financing is a feasible and
sustainable option. The next consideration is the amount
of external assistance required to catalyse NCD service
delivery, followed by which sources of funding are the
most appropriate.
LMICs will have to manage an increasingly complex
portfolio of funding streams as they transition to finan-
cing models that predominantly rely on domestic pre-
pooling. Traditional and emerging donors can help to
bridge the gap with monetary support and technical
assistance. If they are successful the proportion of over-
seas assistance earmarked for NCDs might justifiably
remain low; however, in the short term the disconnect
between financing and the global burden of disease is less
defensible.
The Sustainable Development Agenda is not an
excuse for richer countries to default on commitments
to spend 0.7% of gross national income on overseas
assistance. Nevertheless, even as resource-poor countries
call for more overseas assistance they must begin making
provisions for a future characterised by a growing NCD
burden coupled with increasing international emphasis
on domestic financing. The success of the global NCD
response will be largely dependent on the competence of
poorly resourced countries in managing increasingly
complex blends of funding streams. The future sustain-
ability of NCD funding will be based on domestic and
international leaders prioritising NCD prevention and
control. LMIC governments will also have to formalise
their economies, increase the tax base, and improve the
efficiency of their revenue collection agencies to sustain
government insurance schemes and safeguard future
financing.
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